|
1
|
Hong W, Zheng L, Lu Y, Qiu M, Yan Y, Basharat Z, Zippi M, Zimmer V, Geng W. Non-linear correlation between amylase day 2 to day 1 ratio and incidence of severe acute pancreatitis. Front Cell Infect Microbiol 2022; 12:910760. [PMID: 36483455 PMCID: PMC9723343 DOI: 10.3389/fcimb.2022.910760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 10/20/2022] [Indexed: 12/13/2022] Open
Abstract
Background This study aimed to assess whether the amylase day 2/amylase day 1 ratio was associated with severe acute pancreatitis (SAP). Methods We retrospectively enrolled 464 patients with acute pancreatitis. Serum amylase was measured on admission (day 1) and 24 h later (day 2). Univariable logistic regression with restricted cubic spline analysis, multivariable logistic analysis, and receiver operating characteristic curve analysis was used to evaluate the relationship between the amylase day 2/amylase day 1 ratio and SAP. Results A non-linear association between the amylase day 2/amylase day 1 ratio and SAP was observed. The multivariable logistic analysis confirmed that a high amylase day 2/amylase day 1 ratio (≥0.3) was independently associated with the development of SAP (OR: 6.62). The area under the receiver operating characteristic curve (AUC) of the amylase day 2/amylase day 1 ratio, as a predictive factor for SAP, was 0.65. When amylase ratio ≥0.3 was counted as 1 point and added to the BISAP score to build a new model named the BISAPA (BISAP plus Amylase ratio) score (AUC = 0.86), it improved the diagnostic power of the original BISAP score (AUC = 0.83) for SAP. With a cut-off value of 3, the BISAPA score achieved a sensitivity of 66.0%, a specificity of 86.7%, and diagnostic accuracy of 84.48%. Conclusions There is a non-linear correlation between the amylase day 2/amylase day 1 ratio and the incidence of SAP. BISAPA score might also be a useful tool for the same purpose.
Collapse
Affiliation(s)
- Wandong Hong
- Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China,*Correspondence: Wandong Hong,
| | - Luyao Zheng
- Department of Ultrasonography, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Yajing Lu
- Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Minhao Qiu
- Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Ye Yan
- Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Zarrin Basharat
- Jamil-ur-Rahman Center for Genome Research, Dr. Panjwani Centre for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
| | - Maddalena Zippi
- Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Rome, Italy
| | - Vincent Zimmer
- Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany,Department of Medicine, Marienhausklinik St. Josef Kohlhof, Neunkirchen, Germany
| | - Wujun Geng
- Department of Anesthesiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| |
Collapse
|
|
3
|
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 2016; 29:404-16. [PMID: 27087480 DOI: 10.1111/pcmr.12475] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 03/04/2016] [Indexed: 11/30/2022]
Abstract
The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the current state of melanoma research and care. Intensive discussions among members of the MRF Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and scientists, focused on four thematic areas - diagnosis/early detection, prevention, tumor cell dormancy (including metastasis), and therapy (response and resistance). These discussions extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 International Congress in November. Each of the four groups has outlined their thoughts as per the current status, challenges, and opportunities in the four respective areas. The current state and immediate and long-term needs of the melanoma field, from basic research to clinical management, are presented in the following report.
Collapse
Affiliation(s)
- Glenn Merlino
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Meenhard Herlyn
- Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA
| | - David E Fisher
- Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA, USA
| | - Boris C Bastian
- Departments of Dermatology and Pathology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
| | - Keith T Flaherty
- Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, Charlestown, MA, USA
| | - Michael A Davies
- Department of Genomic Medicine and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer A Wargo
- Department of Genomic Medicine and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Michael J Weber
- Department of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA
| | - Sancy A Leachman
- Department of Dermatology, Knight Cancer Institute Melanoma and Skin Cancer Program, Oregon Health Science University, Portland, OR, USA
| | - Maria S Soengas
- Molecular Oncology Program, Melanoma Laboratory, CNIO, Madrid, Spain
| | - Martin McMahon
- Department of Dermatology, Huntsman Cancer Institute, Salt Lake City, UT, USA
| | - J William Harbour
- Bascom Palmer Eye Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - Susan M Swetter
- Department of Dermatology, Stanford University Medical Center and Cancer Institute/VA Palo Alto Health Care System, Palo Alto, CA, USA
| | - Andrew E Aplin
- Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Michael B Atkins
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
| | - Marcus W Bosenberg
- Department of Dermatology and Dermatopathology, Cancer Center, Yale University, New Haven, CT, USA
| | - Reinhard Dummer
- Department of Dermatology, University of Zurich, Zürich, Switzerland
| | - Jeffrey E Gershenwald
- Department of Genomic Medicine and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Allan C Halpern
- Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Dorothee Herlyn
- Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA
| | | | - John M Kirkwood
- Melanoma and Skin Cancer Program, University of Pittsburgh, Pittsburgh, PA, USA
| | | | - Roger S Lo
- Department of Medical Oncology and Dermatology, University of California Los Angeles, Los Angeles, CA, USA
| | - Georgina V Long
- Melanoma Institute, University of Sydney, Sydney, NSW, Australia
| | - Grant McArthur
- Department of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia
| | - Antoni Ribas
- Department of Medical Oncology and Dermatology, University of California Los Angeles, Los Angeles, CA, USA
| | - Lynn Schuchter
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Jeffrey A Sosman
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical School, Nashville, TN, USA
| | - Keiran S Smalley
- Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| | - Patricia Steeg
- Women Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Nancy E Thomas
- Melanoma Program, Department of Dermatology, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA
| | - Hensin Tsao
- Melanoma and Pigmented Lesion Center, Massachusetts General Hospital, Charlestown, MA, USA
| | - Thomas Tueting
- Department of Dermatology, University of Bonn, Bonn, Germany
| | - Ashani Weeraratna
- Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA
| | - George Xu
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Randy Lomax
- Melanoma Research Foundation, Washington, DC, USA
| | | | | | - Tim Turnham
- Melanoma Research Foundation, Washington, DC, USA
| | - Ze'ev A Ronai
- Tumor Initiation and Maintenance Program, Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| |
Collapse
|